New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients

Area of Science:

• Pharmacology
• Pediatric Transplant Medicine
• Infectious Diseases

Background:

• Cytomegalovirus (CMV) infections are a significant concern post-solid organ transplantation (SOT).
• Valganciclovir (v-GCV) is a common antiviral treatment for CMV in pediatric SOT patients.
• Current v-GCV dosing algorithms may not consistently achieve therapeutic drug exposure.

Purpose of the Study:

• To evaluate existing dosing algorithms for valganciclovir (v-GCV) in pediatric SOT recipients.
• To develop and validate a new, improved v-GCV dosing algorithm for this population.
• To compare the efficacy of different dosing algorithms in achieving target ganciclovir (GCV) exposure.

Main Methods:

• Utilized pharmacokinetic (PK) data from 104 pediatric SOT recipients (kidney, liver, heart) aged 0.3-16.9 years.
• Employed Pmetrics package for R for non-parametric modeling and Monte Carlo simulations.
• Compared the probability of achieving a GCV AUC (area under the curve) of 40-60 mg*h/L across various algorithms, ages, weights, and GFRs.

Main Results:

• GCV clearance was found to be dependent on GFR, with Cockcroft-Gault estimates improving model fit.
• The newly proposed algorithm demonstrated superior performance in achieving target GCV exposure compared to existing methods.
• Only 33% of patients achieved exposure above and 21% within the therapeutic window with current algorithms.

Conclusions:

• A novel, simplified algorithm for initial v-GCV dosing in pediatric SOT patients can standardize plasma drug exposure more effectively.
• The proposed algorithm shows promise in improving therapeutic outcomes by optimizing drug levels.
• Therapeutic drug monitoring (TDM) remains crucial for achieving individualized drug levels within the therapeutic window.